natgillin/translations-raw huggingface dataset:
There is strong evidence of substantial accumulation of tulathromycin in neutrophils and alveolar macrophages. 
Postoje snažni dokazi značajne akumulacije tulatromicina u neutrofilima i alveolarnim makrofagima.
If you notice any side effects, even those not already listed in this package leaflet or you think that the medicine has not worked, please inform your veterinary surgeon. 
Ako zamijetite bilo koju ozbiljnu nuspojavu, čak i one nuspojave koje još nisu opisane u uputi o VMP, ili mislite da veterinarsko-medicinski proizvod ne djeluje, molimo obavijestite svog veterinara.
No such reactions have been observed in pigs and sheep after intramuscular administration. 
Takve reakcije nisu uočene kod svinja i ovaca nakon intramuskularne primjene.
Tulathromycin may cause sensitisation by skin contact. 
Tulatromicin može uzrokovati preosjetljivost u kontaktu s kožom.
The 500 ml vials must not be used for pigs and sheep. 
Bočice od 500 ml ne smiju se upotrebljavati za svinje i ovce.
Draxxin should only be used if pigs are expected to develop the disease within 2-3 days. 
Draxxin treba primjenjivati samo ako se očekuje da će se bolest u svinja razviti za 2 - 3 dana.
However, the in vivo concentration of tulathromycin at the infection site of the lung is not known. 
Međutim, in vivo koncentracija tulatromicina na mjestu infekcije pluća nije poznata.
THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, IF APPLICABLE 
13. RIJEČI „SAMO ZA PRIMJENU NA ŽIVOTINJAMA“ I UVJETI ILI OGRANIČENJA U POGLEDU OPSKRBE I PRIMJENE
Antibiotic treatment of benign foot rot is not considered appropriate. 
Antibiotska terapija benigne zarazne šepavosti ovaca ne smatra se prikladnom.
Pharmacotherapeutic group: Antibacterials for systemic use, macrolides. 
Farmakoterapijska grupa: antibakterijski proizvodi za sustavnu upotrebu, makrolidi.
The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 animals treated displaying adverse reaction(s)) - common (more than 1 but less than 10 animals in 100 animals treated) - uncommon (more than 1 but less than 10 animals in 1,000 animals treated) - rare (more than 1 but less than 10 animals in 10,000 animals treated) - very rare (less than 1 animal in 10,000 animals treated, including isolated reports). 
Učestalost nuspojava je određena sukladno sljedećim pravilima: - vrlo česte (više od 1 na 10 liječenih životinja pokazuju nuspojavu(e) - česte (više od 1 ali manje od 10 životinja na 100 liječenih životinja) - manje česte (više od 1 ali manje od 10 životinja na 1.000 liječenih životinja) - rijetke (više od 1 ali manje od 10 životinja na 10.000 liječenih životinja) - vrlo rijetke (manje od 1 životinje na 10.000 liječenih životinja, uključujući izolirane slučajeve).
Tulathromycin concentrations in lung homogenate were considerably higher than those in plasma. 
Koncentracije tulatromicina u homogenatu plućnog tkiva bile su znatno više od onih u plazmi.
Increased minimum inhibitory concentration (MIC) values have been found in some isolates of Histophilus somni and Actinobacillus pleuropneumoniae. 
Povišene vrijednosti minimalne inhibitorne koncentracije (MIK) pronađene su u nekim izolatima Histophilus somni i Actinobacillus pleuropneumoniae.
Monothioglycerol 
Monotioglicerol
Pigs and sheep: For intramuscular use. 
Svinje i ovce: intramuskularna primjena.
Macrolides are bacteriostatic acting antibiotics and inhibit essential protein biosynthesis by virtue of their selective binding to bacterial ribosomal RNA. 
Makrolidi su antibiotici koji djeluju bakteriostatski i inhibiraju biosintezu esencijalnih bjelančevina uslijed njihova selektivnog vezanja na bakterijsku ribosomsku RNK.
For any respiratory disease, it is recommended to treat animals in the early stages of the disease and to evaluate the response to treatment within 48 hours after injection. 
U slučaju bolesti dišnih puteva preporučuje se liječiti životinje u ranim stadijima bolesti i procijeniti reakciju na liječenje unutar 48 sati nakon injiciranja.
Tulathromycin is a semi-synthetic macrolide antimicrobial agent, which originates from a fermentation product. 
Tulatromicin je polusintetičko makrolidno antimikrobno sredstvo koje potječe od produkta fermentacije.
Subcutaneous administration of Draxxin to cattle causes very commonly transient pain reactions and local swellings at the injection site that can persist for up to 30 days. 
Subkutana primjena Draxxina kod goveda često uzrokuje prolazne bolne reakcije i lokalne otekline na mjestu injiciranja koje mogu potrajati do 30 dana.
The safety of the veterinary medicinal product has not been established during pregnancy and lactation. 
Neškodljivost veterinarsko-medicinskog proizvoda nije utvrđena tijekom graviditeta i laktacije.
It is recommended to treat animals in the early stages of the disease and to evaluate the response to treatment within 48 hours after injection. 
Preporučuje se liječiti životinje u ranim stadijima bolesti i procijeniti reakciju na liječenje unutar 48
It lowers the production of the pro-inflammatory mediators leukotriene B4 and CXCL-8 and induces the production of anti-inflammatory and pro-resolving lipid lipoxin A4. 
Smanjuje proizvodnju protu-upalnog medijatora leukotriena B4 i CXCL-8 te inducira proizvodnju protuupalnih i „pro-resolvnig“ lipida lipoksin A4.
In case of accidental eye exposure, flush the eyes immediately with clean water. 
U slučaju nehotičnog izlaganja oka, odmah isperite oči čistom vodom.
11R, 12S, 13S, 
8R, 10R, 11R,
The presence of the disease in the herd should be established before metaphylactic treatment. 
Prije metafilaktičnog liječenja treba ustanoviti prisutnost bolesti u stadu.
Cattle: SC. Pigs and sheep: IM. 
Goveda: s.c. Svinja i ovce: i.m.
Treatment of foot rot should therefore be undertaken along with other flock management tools, for example providing dry environment. 
Liječenje zarazne šepavosti ovaca stoga treba poduzeti zajedno s drugim mjerama za upravljanje stadom, na primjer osiguravanje suhog okruženja.
The maximum concentration (Cmax) in plasma was approximately 0.6 µg/ml; this was achieved approximately 30 minutes post-dosing (Tmax). 
Maksimalna koncentracija (Cmax) u plazmi bila je približno 0,6 µg/ml; ta je vrijednost postignuta približno 30 minuta nakon primjene (Tmax).
Tulathromycin 
Tulatromicin
Antiinfectious agents/ Antibiotics' 
Antiinfektiv ni agensi/Antib iotici
The maximum concentration (Cmax) in plasma was approximately 0.5 µg/ml; this was achieved approximately 30 minutes post-dosing (Tmax). 
Maksimalna koncentracija (Cmax) u plazmi bila je približno 0,5 µg/ml; ta je vrijednost postignuta približno 30 minuta nakon primjene (Tmax).
The bioavailability of tulathromycin after intramuscular administration in pigs was approximately 88%. 
Bioraspoloživost tulatromicina nakon intramuskularne primjene na svinjama bila je približno 88%.
In case of accidental spillage onto skin, wash the skin immediately with soap and water. 
U slučaju nehotičnog prolijevanja po koži, odmah isperite sapunom i vodom.
Treatment of the early stages of infectious pododermatitis (foot rot) associated with virulent Dichelobacter nodosus requiring systemic treatment. 
Liječenje ranih faza zaraznog pododermatitisa (šepavosti) povezanog sa zarazom Dichelobacter nodosus zahtijeva sustavnu terapiju.
Draxxin showed limited efficacy in sheep with severe clinical signs or chronic foot rot, and should therefore only be given at an early stage of foot rot. 
Draxxin je pokazao ograničenu učinkovitost u ovaca s težim kliničkim znakovima ili kronične zarazne šepavosti, pa ga stoga treba dati samo u ranoj fazi zarazne šepavosti ovaca.
The bioavailability of tulathromycin after subcutaneous administration in cattle was approximately 90%. 
Bioraspoloživost tulatromicina nakon subkutane primjene u goveda bila je približno 90%.
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements. 
6.6 Posebne mjere predostrožnosti za odlaganje neupotrebljenog veterinarsko-medicinskog proizvoda ili otpadnih materijala dobivenih primjenom tih proizvoda Bilo koji neupotrebljeni veterinarsko-medicinski proizvod ili otpadni materijali dobiveni primjenom tih veterinarsko-medicinskih proizvoda trebaju se odlagati u skladu s lokalnim propisima.
Peak concentrations were followed by a slow decline in systemic exposure with an apparent elimination half-life (t1/2) of approximately 91 hours in plasma. 
Nakon vršnih koncentracija uslijedio je spori pad sustavne izloženosti s prividnim poluvijekom eliminacije (t1/2) od približno 91 sata u plazmi.
Cattle: For subcutaneous use. 
Goveda: subkutana primjena.
Peak concentrations were followed by a slow decline in systemic exposure with an apparent elimination half-life (t1/2) of 90 hours in plasma. 
Nakon vršnih koncentracija uslijedio je spori pad sustavne izloženosti s prividnim poluvijekom eliminacije (t1/2) od 90 sati u plazmi.
Interaction with other medicinal products and other forms of interaction: Do not administer simultaneously with antimicrobials with a similar mode of action such as other macrolides or lincosamides. 
Interakcije s drugim medicinskim proizvodima i drugi oblici interakcija: Ne primjenjivati proizvod istovremeno s drugim antimikrobnim sredstvima sa sličnim načinom djelovanja kao što su makrolidi ili linkozamidi.
In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician. 
U slučaju nehotičnog samoinjiciranja odmah potražite pomoć liječnika i pokažite mu uputu o VMP ili etiketu.
Draxxin 25 mg/ml: Zoetis Belgium SA Rue Laid Burniat 1 1348 Louvain-la-Neuve BELGIUM 
ŠPANJOLSKA Draxxin 25 mg/ml: Zoetis Belgium SA Rue Laid Burniat 1
Bovine 300 µg/kg 200 µg/kg 
Goveda 300 µg/kg 200 µg/kg
For multiple vial entry, an aspirating needle or multi-dose syringe is recommended to avoid excessive broaching of the stopper. 
Za višestruko otvaranje bočice, preporuča se korištenje posebne igle za navlačenje ili automatska brizgaljka za višekratno apliciranje u svrhu sprječavanja prekomjernog otvaranja bočice.
To ensure correct dosage bodyweight should be determined as accurately as possible to avoid underdosing. 
Da bi se osiguralo pravilno doziranje, potrebno je što preciznije odrediti tjelesnu težinu kako bi se izbjeglo davanje premalene doze.
generally giving rise to cross-resistance with lincosamides and group B streptogramins (MLSB resistance); by enzymatic inactivation; or by macrolide efflux. 
rRNK, što općenito pobuđuje križnu otpornost s linkozamidima i streptograminima skupine B (MLSB rezistentnost); enzimskom inaktivacijom; ili makrolidnim efluksom.
Do not administer simultaneously with antimicrobials with a similar mode of action such as other macrolides or lincosamides. 
Ne primjenjivati istovremeno s antimikrobnim sredstvima sa sličnim načinom djelovanja, primjerice s drugim makrolidima ili linkozamidima.
The bioavailability of tulathromycin after intramuscular administration in sheep was 100%. 
Bioraspoloživost tulatromicina nakon intramuskularne primjene u ovaca iznosila je 100%.
Marker residue Animal species 
Marker rezidue
Do not use simultaneously with other macrolides or lincosamides. 
Ne primjenjivati istovremeno s drugim makrolidima ili linkozamidima.
Marketing authorisation holder and manufacturer responsible for batch release: Zoetis Belgium SA 
Nositelj odobrenja za stavljanje u promet i proizvođač odgovoran za puštanje serije u promet: Zoetis Belgium SA
14R)-2-ethyl tetrahydroxy hexamethyl trideoxy-3(dimethylamin o)-ß-Dxylohexopyranosyl]oxy]-1oxa-6azacyclopentde-can-15-one expressed as tulathromycin equivalents 
ksiloheksopira nosil]oksi]-1oksa-6azaciclopent-decan-15-one izražen kao ekvivalenti tulatromicina
In addition to its antimicrobial properties, tulathromycin demonstrates immune-modulating and antiinflammatory actions in experimental studies. 
Osim svojih antimikrobnih svojstava, u eksperimentalnim istraživanjima pokazalo se i njegovo svojstvo imunološkog moduliranja i protuupalno djelovanje.
Tulathromycin also possesses in vitro activity against Moraxella bovis, the bacterial pathogen most commonly associated with infectious bovine keratoconjunctivitis (IBK). 
Tulatromicin također ima in vitro djelovanje protiv Moraxella bovis, bakterijskog patogena koji je najčešće povezan sa zaraznim keratokonjunktivitisom goveda (IBK).
Ovine, caprine 
Ovce, koze
Porcine 800 µg/kg 300 µg/kg 
Svinje 800 µg/kg 300 µg/kg
4.8 Interaction with other medicinal products and other forms of interaction 
4.8 Interakcije s drugim medicinskim proizvodima i drugi oblici interakcija Javlja se križna rezistencija s drugim makrolidima.
Read the package leaflet before use. 
Prije upotrebe pročitajte uputu.
For subcutaneous use. 
Za subkutanu primjenu.
B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE 
UVJETI ILI OGRANIČENJA ODOBRENJA ZA STAVLJANJE U PROMET U POGLEDU OPSKRBE ILI PRIMJENE
Vial sizes: 20 ml, 50 ml, 100 ml, 250 ml and 500 ml. 
Veličine bočica: 20 ml, 50 ml, 100 ml, 250 ml i 500 ml.
Manufacturers responsible for batch release: FAREVA AMBOISE 
FAREVA AMBOISE Zone Industrielle,
The safety of tulathromycin during pregnancy and lactation has not been established in cattle and pigs. 
Neškodljivost tulatromicina tijekom graviditeta i laktacije nije utvrđena.
In vitro activity against Dichelobacter nodosus (vir), the bacterial pathogen most commonly associated with infectious pododermatitis (foot rot) in sheep has been demonstrated. 
Dichelobacter nodosus (vir), dokazano je, da je bakterijski patogen najčešće povezan sa zaraznim pododermatitisom (zarazna šepavost) u ovaca.
Monothioglycerol Propylene glycol Citric acid Hydrochloric acid Sodium hydroxide Water for injections 
Klorovodična kiselina Natrijev hidroksid Voda za injekcije
In cattle at dosages of three, five or ten times the recommended dose, transient signs attributed to injection site discomfort were observed and included restlessness, head-shaking, pawing the ground, and brief decrease in feed intake. 
Kod goveda predoziranih trostrukom, peterostrukom ili deseterostrukom preporučenom dozom uočeni su prolazni znakovi koji se pripisuju nelagodi na mjestu injiciranja i uključuju nemir, tresenje glavom, kopanje zemlje papkom i kratkotrajni gubitak apetita.
Do not use in pregnant cows or heifers, which are intended to produce milk for human consumption, within 2 months of expected parturition. 
Ne primjenjivati na gravidnim kravama ili junicama koje su namijenjene za proizvodnju mlijeka za ljudsku upotrebu,u roku od 2 mjeseca od očekivanog poroda.
Clear colourless to slightly yellow solution. 
Bistra bezbojna do žućkasta otopina.
Cattle (meat and offal): 22 days. 
Goveda (meso i jestive iznutrice): 22 dana.
In lambs (approx. 6 weeks old), at dosages of three or five times the recommended dose, transient signs attributed to injection site discomfort were observed, and included walking backwards, head shaking, rubbing the injection site, lying down and getting up, bleating. 
U janjadi (starih približno 6 tjedana), prilikom doziranja od tri ili pet puta veće doze od preporučene, zabilježeni su prolazni znakovi pripisani nelagodi na mjestu injiciranja, što uključuje hodanje unatrag, tresenje glavom, trljanje mjesta ubrizgavanja, ležanje i ustajanje, blejanje.
Resistance to macrolides can develop by mutations in genes encoding ribosomal RNA (rRNA) or some ribosomal proteins; by enzymatic modification (methylation) of the 23S rRNA target site, generally giving rise to cross-resistance with lincosamides and group B streptogramins (MLSB resistance); by enzymatic inactivation; or by macrolide efflux. 
ili neke ribosomske proteine; enzimskom modifikacijom (metilacijom) ciljnog mjesta 23S rRNK, što općenito pobuđuje križnu otpornost s linkozamidima i streptograminima skupine B (MLSB rezistencija); enzimskom inaktivacijom; ili makrolidnim efluksom.
Pigs (meat and offal): 13 days. 
Svinje (meso i jestive iznutrice): 13 dana.
Pathomorphological injection site reactions (including reversible changes of congestion, oedema, fibrosis and haemorrhage) are present for approximately 30 days after injection. 
Patomorfološke reakcije na mjestu injiciranja (uključujući reverzibilne promjene kongestije, edeme, fibroze i krvarenja) prisutne su približno do 30 dana nakon injiciranja.
Sheep (meat and offal): 16 days. 
Ovce (meso i jestive iznutrice): 16 dana.
EXP Once broached use by 
Jednom otvoren, upotrijebiti do
For treatment of cattle over 300 kg bodyweight, divide the dose so that no more than 7.5 ml are injected at one site. 
Prilikom liječenja goveda težih od 300 kg, dozu treba podijeliti tako da se na jedno mjesto aplicira najviše 7,5 ml.
In both bovine and porcine polymorphonuclear cells (PMNs; neutrophils), tulathromycin promotes apoptosis (programmed cell death) and the clearance of apoptotic cells by macrophages. 
U polimorfonuklearnim stanicama (PMN, neutrofili)goveda i svinja, tulatromicin potiče apoptozu (programirana smrt stanice) i klirens apoptoze stanica pomoću makrofaga.
PARTICULARS TO APPEAR ON THE OUTER PACKAGE Cardboard box (20 ml / 50 ml / 100 ml / 250 ml) 
PODACI KOJI SE MORAJU NALAZITI NA VANJSKOM PAKOVANJU Kartonska kutija (20 ml / 50 ml / 100 ml / 250 ml)
Following intravenous dosing the volume of distribution at steady-state (Vss) was 31.7 l/kg. 
Nakon intravenoznog doziranja volumen raspodjele u stanju ravnoteže (Vss) bio je 31,7 l/kg.
PARTICULARS TO APPEAR ON THE OUTER PACKAGE Cardboard box (500 ml) 
PODACI NA VANJSKOM PAKOVANJU Kartonska kutija (500 ml)
Do not use in pregnant animals, which are intended to produce milk for human consumption, within 2 months of expected parturition. 
Ne primjenjivati na gravidnim životinjama koje su namijenjene za proizvodnju mlijeka za ljudsku upotrebu, u roku od 2 mjeseca od očekivanog poroda.
5 mg/ml For the full list of excipients, see section 6.1. 
Potpuni popis pomoćnih tvari vidi u odjeljku 6.1.
Primary packaging: Type I glass vial with a fluoropolymer coated chlorobutyl stopper and an aluminium overseal. 
I s klorobutilnim čepom, obloženim fluoropolimerom i aluminijskom kapicom.
Treatment of infectious bovine keratoconjunctivitis (IBK) associated with Moraxella bovis sensitive to tulathromycin. 
IBK) uzrokovanog bakterijom Moraxella bovis koja je osjetljiva na tulatromicin.
Pathomorphological injection site reactions (including reversible changes of congestion, oedema, fibrosis and haemorrhage) are very common for approximately 30 days after injection in cattle and pigs. 
Patomorfološke reakcije na mjestu injiciranja (uključujući reverzibilne promjene kongestije, edeme, fibroze i krvarenja) vrlo su česte približno 30 dana nakon injiciranja u goveda i svinja.
It differs from many other macrolides in that it has a long duration of action that is, in part, due to its three amine groups; therefore it has been given the chemical subclass designation of triamilide. 
Razlikuje se od mnogih drugih makrolida po tome što ima dugotrajno djelovanje koje je, djelomično, rezultat njegovih triju amino skupina; stoga je razvrstan u podskupinu triamilida.
In young pigs weighing approximately 10 kg given three or five times the therapeutic dose transient signs attributed to injection site discomfort were observed and included excessive vocalisation and restlessness. 
Kod odojaka od približno 10 kg koji su dobili trostruku ili peterostruku terapijsku dozu uočeni su prolazni znakovi koji se pripisuju boli na mjestu injiciranja i uključuju pretjerano glasanje i nemir.
In sheep, the pharmacokinetic profile of tulathromycin, when administered as a single intramuscular dose of 2.5 mg/kg bodyweight, achieved a maximum plasma concentration (Cmax) of 1.19 µg/ml in approximately 15 minutes (Tmax) post-dosing and had an elimination half-life (t1/2) of 69.7 hours. 
U ovaca, farmakokinetički profil tulatromicina primijenjenog u 1 dozi od 2,5 mg/kg tjelesne težine intramuskularnim putem, maksimalnu koncentraciju u plazmi (Cmax) od 1,19 µg/ml postiže unutar 15
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS Vial (50 ml) 
OSNOVNI DIJELOVI NAPISANI NA MALIM JEDINICAMA UNUTARNJIH PAKOVANJA Bočica (50 ml)
Resistance to macrolides can develop by mutations in genes encoding ribosomal RNA (rRNA) or some ribosomal proteins; by enzymatic modification (methylation) of the 23S rRNA target site, 
(rRNK) ili neke ribosomske proteine; enzimskom modifikacijom (metilacijom) ciljnog mjesta 23S
For treatment of pigs over 80 kg bodyweight, divide the dose so that no more than 2 ml are injected at one site. 
Pri liječenju svinja težih od 80 kg tjelesne težine, dozu treba podijeliti tako da se na jedno mjesto aplicira najviše 2 ml.
A. MANUFACTURERS RESPONSIBLE FOR BATCH RELEASE 
PROIZVOĐAČI ODGOVORNI ZA PUŠTANJE SERIJE U PROMET
PARTICULARS TO APPEAR ON THE OUTER PACKAGE Cardboard box (50 ml / 100 ml / 250 ml) 
PODACI NA VANJSKOM PAKOVANJU Kartonska kutija (50 ml / 100 ml / 250 ml)
Lameness was also observed when the hind leg was used as the injection site. 
Uočena je i šepavost ako je injekcija ubrizgana u stražnji ekstremitet.
In cattle, the pharmacokinetic profile of tulathromycin when administered as a single subcutaneous dose of 2.5 mg/kg bodyweight, was characterised by rapid and extensive absorption followed by high distribution and slow elimination. 
Kada je tulatromicin primijenjen govedima kao pojedinačna subkutana doza od 2,5 mg/kg tjelesne težine, njegov je farmakokinetički profil bio karakteriziran vrlo brzom i ekstenzivnom apsorpcijom nakon koje je uslijedila opsežna distribucija i spora eliminacija.
Not for use in animals from which milk is produced for human consumption. 
Nije za primjenu na životinjama čije mlijeko se koristi za ljudsku uporabu.
In pigs, the pharmacokinetic profile of tulathromycin when administered as a single intramuscular dose of 2.5 mg/kg bodyweight, was also characterised by rapid and extensive absorption followed by high distribution and slow elimination. 
Kada je tulatromicin bio primijenjen na svinjama kao pojedinačna intramuskularna doza od 2,5 mg/kg tjelesne težine, njegov je farmakokinetički profil također bio karakteriziran vrlo brzom i ekstenzivnom apsorpcijom nakon koje je uslijedila opsežna distribucija i spora eliminacija.
For treatment of pigs over 40 kg bodyweight, divide the dose so that no more than 4 ml are injected at one site. 
Pri liječenju svinja težih od 40 kg, dozu treba podijeliti tako da se na jedno mjesto aplicira najviše 4
Name and address of the manufacturers responsible for batch release 
PROIZVOĐAČI ODGOVORNI ZA PUŠTANJE SERIJE U PROMET Naziv i adresa proizvođača odgovornih za puštanje serije u promet
The volume of distribution at steady-state (VSS) determined after intravenous administration was 11 l/kg. 
Volumen raspodjele u stanju ravnoteže (Vss) utvrđen nakon intravenske primjene bio je 11 l/kg.
The volume of distribution at steady-state (Vss) determined after intravenous administration was 11 l/kg. 
Volumen raspodjele u stanju ravnoteže (Vss) utvrđen nakon intravenske primjene bio je 11 L/kg.
Draxxin 100 mg/ml solution for injection for cattle tulathromycin 
Draxxin 100 mg/ml otopina za injekciju za goveda tulatromicin
PACKAGE LEAFLET: Draxxin 25 mg/ml solution for injection for pigs 
UPUTA O VMP: Draxxin 25 mg/ml otopina za injekciju za svinje
Vial sizes: 50, 100 and 250 ml. 
Veličine bočica: 50 ml, 100 ml i 250 ml.
QUANTITY OF THE ACTIVE SUBSTANCE(S) 
KOLIČINA DJELATNIH TVARI
Draxxin 25 mg/ml solution for injection for pigs 
Draxxin 25 mg/ml otopina za injekciju za svinje
Tulathromycin possesses in vitro activity against Mannheimia haemolytica, Pasteurella multocida, Histophilus somni and Mycoplasma bovis, and Actinobacillus pleuropneumoniae, Pasteurella multocida, Mycoplasma hyopneumonia, Haemophilus parasuis and Bordetella bronchiseptica the bacterial pathogens most commonly associated with bovine and swine respiratory disease, respectively. 
Tulatromicin je in vitro učinkovit protiv bakterija i mikoplazme: Mannheimia haemolytica, Pasteurella multocida, Histophilus somni i Mycoplasma bovis, te Actinobacillus pleuropneumoniae, Pasteurella multocida, Mycoplasma hyopneumoniae, Haemophilus parasuis i Bordetella bronchiseptica, bakterijskih patogena koji su najčešće povezani s respiratornim bolestima goveda, odnosno svinja.